Clinical trials: Epithelial Cancer, open to volunteers
Hepatocellular Carcinoma
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver tumour and is the fourth leading cause of cancer-related death worldwide.
- Trial name
- NCT05359939
- Testing
- 18F-FDGal PET/CT versus 18F-choline PET/CT
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Hepatocellular Carcinoma
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
This is a multicentre randomised 3-arm phase II clinical trial in patients with resectable Hepatocellular Carcinoma (HCC). Sixty patients will be randomized 1:1:1 to 6 weeks of pre-operative therapy with: pembrolizumab…
- Trial name
- PRIMER-1 (NCT05185739)
- Testing
- Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
Esophageal Squamous Cell Carcinoma
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
This is a prospective, multi-cohort, exploratory clinical study designed to evaluate the efficacy and safety of neoadjuvant adebrelimab combined with chemotherapy in patients with resectable locally advanced thoracic esophageal…
- Trial name
- NCT07452601
- Testing
- Adebrelimab plus nab-paclitaxel and cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study
This is a multicenter, open-label, single-arm, prospective Phase II clinical trial. The study enrolls patients with extrahepatic cholangiocarcinoma or gallbladder carcinoma who have undergone curative resection and harbor…
- Trial name
- NCT07636824
- Testing
- Postoperative radiotherapy, Capecitabine or S-1
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Thyroid, Papillary Thyroid Cancer
A Study of Online Follow-up in Patients With Papillary Thyroid Cancer
The randomized, actively controlled, non-inferiority trial is scheduled to begin in August 2024 and run through August 2026. Inclusion criteria: (1) has undergone microwave ablation of thyroid or thyroidectomy (including…
- Trial name
- NCT06800482
- Testing
- online outpatient follow-up
- Where
- China
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Phase II, Ivonescimab
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).
- Conditions
- Phase II, Ivonescimab, Intraperitoneal, Paclitaxel
- Trial name
- NCT07753824
- Testing
- Ivonescimab, IP PTX
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Brain Cancer, Glioma
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring.
- Trial name
- NCT00870129
- Testing
- MRI and advanced MRI sequences
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
The goal of this clinical trial is to evaluate whether formulated methylene blue can safely and effectively treat advanced or inoperable Squamous Cell Carcinoma (SCC), a common type of skin cancer.
- Conditions
- SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin, Inoperable Disease
- Trial name
- NCT07311057
- Testing
- Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Daryoush Hamidi Alamdari, PhD
Bladder Cancer
Blue Light Cystoscopy With Cysview® Registry
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
- Trial name
- BLCCR (NCT02660645)
- Testing
- Hexaminolevulinate hydrochloride (HCL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- Where
- 23 sites in United States
- Volunteers
- 4,400 people
- Sponsor
- Photocure
Diffuse Midline Glioma (DMG), Glioblastoma
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other…
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
- Trial name
- PNOC023 (NCT04732065)
- Testing
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Where
- 7 sites in United States, Netherlands and 1 more
- Volunteers
- 208 people
- Sponsor
- Sabine Mueller, MD, PhD
High-Grade Glioma
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA…
- Trial name
- NCT06829173
- Testing
- XRD-0394, Radiation Therapy, Surgical Resection
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- NYU Langone Health
Esophageal Cancer, Chemoradiotherapy
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory.
- Trial name
- EC-CRT-008 (NCT07177794)
- Testing
- toripalimab, capecitabine
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Sun Yat-sen University
Oligodendroglioma, Low-grade Oligodendroglioma
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration.
- Conditions
- Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion
- Trial name
- POLO (NCT04702581)
- Testing
- PCV chemotherapy, Radiotherapy and PCV chemotherapy
- Where
- 26 sites in France
- Volunteers
- 280 people
- Sponsor
- Hospices Civils de Lyon
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat…
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV Associated Cancers
- Trial name
- NCT07578467
- Testing
- ATRN-119, Stereotactic Body Radiation Therapy (SBRT)
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Cancer, Thyroid Cancer
Pharmaceutical Management in Targeted Radioligand Therapy
Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues.
- Conditions
- Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
- Trial name
- PharmTRT (NCT07389512)
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma (HCC)
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based…
- Trial name
- CHANCE2421 (NCT06876753)
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR…
- Trial name
- NCT05062837
- Testing
- Hepatectomy Combined With Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Recurrent Glioblastoma
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive…
- Trial name
- NCT05540275
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Provincial People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.